인사이트

Insights From Our Experts

Articles

Establishing the Patient Access Mission During Clinical Development

An inescapable but disappointing characteristic of pharmaceutical research and development is that at the end of a process costing billions of dollars, the majority of launches fail to reach expectations. The ultimate tragedy of this is…

EVERSANA’s Continued Commitment to Rare Disease

World Orphan Drug Congress USA 2022 As a continued commitment to the rare disease space, EVERSANA was a proud sponsor and participant of this year’s World Orphan Drug Congress USA (WODC). Leaders including Maria Kirsch, General…

WEBINAR: A Pivotal Shift in Life Sciences Industry Across R&D and Commercial: A Conversation with the Experts

The life sciences pipeline is evolving from small molecules to biologics and cell and gene therapy, and there are currently more than 900 therapies in clinical trials. As competition rises, manufacturers also need to manage the…

Navigating the Transition to Post-Approval Pharmacovigilance With EVERSANA and ArisGlobal

Partnering with a contract research organization (CRO) provider during clinical development fills an important role in the product life cycle, providing pharmaceutical companies with pharmacovigilance expertise and support during clinical trials. After product approvals, it can…

Breaking Up Is Hard to Do: When to Leave Your CRO for Optimized Pharmacovigilance

During an intense year for biopharma innovation, the industry’s rapid growth is spotlighting a global need to bring pharmacovigilance practices up to speed. Executing superior pharmacovigilance practices from clinical trials throughout the product life cycle is…

Supporting Successful Commercialization With Integrated Compliance

Compliance is an integral part of the entire biopharma, medical device and product lifecycle, yet it poses one of the biggest challenges for our customers. While they try to focus on driving value, innovation and patient…

The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?

Time and strategy are keys to launching in an overwhelmed, unpredictable market. Pharmaceutical companies in mid-development of a drug need to look ahead at their launch strategy options and consider what market conditions could look like by the time they’re ready to commercialize their product.  By evaluating the value…

Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement

EVERSANA was proud to participate in this year’s brand-new session “End-To-End Patient Engagement: From Clinical Trials Through Patient Support Programs.“ Bhaskar Sambasivan, Chief Strategy Officer and President of Patient Services, provided valuable insight into the emerging…

COVID-19 Vaccine Safety Briefing Report

As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug…

What Happens After a COVID-19 Vaccine Trial Succeeds? 4 Pharmacovigilance Challenges to Address During Commercialization

As pharma companies continue to develop COVID-19 vaccines around the world, they are faced with these questions: What happens when we succeed? How will we quickly and safely distribute the vaccine globally? Pulling off this rapid,…